<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523809</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0873</org_study_id>
    <nct_id>NCT00523809</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor</brief_title>
  <official_title>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if giving Avastin (bevacizumab) with&#xD;
      standard chemotherapy and a blood stem cell transplant, in patients with an advanced solid&#xD;
      tumor, can help to shrink the tumor or slow its growth. The safety of this treatment will&#xD;
      also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the&#xD;
      growth of blood vessels.&#xD;
&#xD;
      The combination of standard chemotherapy drugs (fludarabine and melphalan) used for this&#xD;
      study may help to improve the chances of your body accepting the stem cell transplant.&#xD;
      Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic&#xD;
      material of cells) and weaken the immune system so that stem cells can stay in your body.&#xD;
      Melphalan is designed to damage the cancer cells' DNA.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will have a central venous&#xD;
      catheter inserted. A central venous catheter is a sterile flexible tube that will be placed&#xD;
      into a large vein while you are under local anesthesia. Your doctor will explain this&#xD;
      procedure to you in more detail, and you will be required to sign a separate consent form for&#xD;
      this procedure.&#xD;
&#xD;
      You will receive chemotherapy with bevacizumab, fludarabine, and melphalan in order to&#xD;
      prepare for the stem cell transplant.&#xD;
&#xD;
      On Day 1, you will receive bevacizumab through a needle in your vein over 30 minutes.&#xD;
&#xD;
      On Days 2-6, you will receive fludarabine by vein over 30 minutes.&#xD;
&#xD;
      On Day 5-6, you will receive melphalan by vein over 30 minutes.&#xD;
&#xD;
      On Day 7, you will receive no study drugs.&#xD;
&#xD;
      Stem Cell Transplant and Post-Transplant Drug Administration:&#xD;
&#xD;
      On Day 8, you will have a stem cell transplant. Your study doctor will explain this procedure&#xD;
      to you in more detail and you will sign a separate consent form.&#xD;
&#xD;
      After the transplant, you will receive the drugs tacrolimus and methotrexate. Tacrolimus and&#xD;
      methotrexate are used to prevent graft versus host disease (GVHD), a condition that occurs&#xD;
      when the transplanted cells attack the normal cells in the body.&#xD;
&#xD;
      Tacrolimus will be given by vein non-stop (24 hours a day) until you are able to take&#xD;
      medications by mouth. Once you are able to take medications by mouth, your doctor will tell&#xD;
      you how and when to take the oral medication. You will receive tacrolimus for 2-3 months.&#xD;
      During the last month that tacrolimus is given, the dose will be lowered gradually.&#xD;
&#xD;
      Methotrexate will be given by vein over a few seconds on Days 9, 11, and 14. An additional&#xD;
      dose of methotrexate will be given on Day 19 if your donor is your parent, child, or an&#xD;
      unrelated family member.&#xD;
&#xD;
      If GVHD does occur, the GVHD will be treated with methylprednisolone by vein or by mouth, as&#xD;
      needed. You may also be given steroid cream to use on the skin, if needed.&#xD;
&#xD;
      Starting at least 3 weeks after the transplant, as soon as your blood counts recover, you&#xD;
      will receive bevacizumab every 2 weeks by vein over 30 minutes.&#xD;
&#xD;
      Post-Transplant Procedures:&#xD;
&#xD;
      You must stay in the hospital for about 3-4 weeks beginning on Day 1. While you are in the&#xD;
      hospital, blood (about 2 teaspoons) will be drawn for routine tests every day.&#xD;
&#xD;
      You must stay in the Houston area for about 100 days after the transplant. Once a month&#xD;
      during the 100 days after the transplant, and then every 3 months for the first year, you&#xD;
      will have scans to check the status of the disease. The study doctor will decide which scans&#xD;
      are necessary (chest x-rays, CT scans, and/or bone scans). You may also have a bone marrow&#xD;
      aspirate and biopsy at these times. The bone marrow aspirate and biopsy would only be&#xD;
      performed if your bone marrow was shown to be involved with the disease at the time of&#xD;
      screening.&#xD;
&#xD;
      If the disease is still present at 2 months after the transplant, and you do not have GVHD,&#xD;
      you will stop receiving tacrolimus within 2 weeks. After that, if the disease is still&#xD;
      present after another 6 weeks, and you do not have GVHD, you may receive an infusion of donor&#xD;
      lymphocytes (a type of white blood cell) by vein over about 30 minutes. This treatment with&#xD;
      white blood cells may be repeated 2 more times with 6 weeks between each infusion.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be taken off-study after 1 year.&#xD;
&#xD;
      Follow-Up Visits:&#xD;
&#xD;
      You will have follow-up visits as per standard of care.&#xD;
&#xD;
      This is an investigational study. The use of bevacizumab in transplant patients is not FDA&#xD;
      approved. Melphalan and fludarabine are FDA approved and commercially available for&#xD;
      transplant patients. Up to 18 patients will take part in this study. All will be enrolled at&#xD;
      M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>100 days after transplant</time_frame>
    <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg IV Daily Over 30 Minutes for 1 Day</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>Avastinâ„¢</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Stem Cell Transplantation on Day 8.</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2 IV Daily Over 30 Minutes for 5 Days</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m^2 IV Daily Over 30 Minutes for 2 Days</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.</description>
    <arm_group_label>Bevacizumab + Fludarabine + Melphalan</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Antithymocyte Globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. From Age 18 to Age &lt;/= 65 years old.&#xD;
&#xD;
          2. Patients must have one of the following diseases. 1) metastatic breast cancer which&#xD;
             achieved a tumor response (complete response (CR) or partial response (PR)) by&#xD;
             pre-transplant therapy. For bone only metastatic breast cancer, a tumor response of&#xD;
             stable disease (SD) is accepted. 2) low grade advanced ovarian cancer 3) high grade&#xD;
             advanced ovarian cancer which achieved antitumor response (CR or PR) by pre-transplant&#xD;
             therapy.&#xD;
&#xD;
          3. Zubrod performance status &lt;/= 1.&#xD;
&#xD;
          4. An HLA-matched (6/6 matches) related donor or unrelated donor (8/8 matches) willing&#xD;
             and able to donate peripheral blood stem cell (PBSC) or bone marrow and/or lymphocytes&#xD;
             by conventional techniques.&#xD;
&#xD;
          5. Requirement of prior treatment. For metastatic renal cell carcinoma (RCC) two prior&#xD;
             treatments, which include targeted therapy (e.g. Sorafenib and Stutent). For breast&#xD;
             and ovarian cancer, one prior treatment which include chemotherapy.&#xD;
&#xD;
          6. Adequate major organ functions.&#xD;
&#xD;
          7. Signed informed consent.&#xD;
&#xD;
          8. Left ventricular ejection fraction &gt;/= 45%. Cardiology clearance is needed if the&#xD;
             patient has left ventricular ejection fraction of &lt; 45%, uncontrolled arrhythmias, or&#xD;
             symptomatic cardiac disease.&#xD;
&#xD;
          9. Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), and carbon&#xD;
             monoxide diffusing capacity (DLCO) &gt;/= 50% of predicted value. Pulmonary clearance is&#xD;
             needed if the patient has FEV1, FVC, or DLCO &lt; 50% of predicted valued or any&#xD;
             symptomatic pulmonary disease.&#xD;
&#xD;
         10. Serum creatinine &lt;/= 2.0 mg/dL, or creatinine clearance &gt; 40 mL/min.&#xD;
&#xD;
         11. Serum bilirubin &lt;/= 1.5 mg/dL, and serum glutamic-pyruvic transaminase (SGPT) &lt;/= 3 *&#xD;
             upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of allogeneic stem cell transplantation.&#xD;
&#xD;
          2. Life expectancy is severely limited by concomitant illness.&#xD;
&#xD;
          3. Clinically significant active infections.&#xD;
&#xD;
          4. HIV infection.&#xD;
&#xD;
          5. Chronic active hepatitis.&#xD;
&#xD;
          6. Pregnant or lactating women.&#xD;
&#xD;
          7. Presence of, or prior history of multiple brain metastasis. If patient has prior&#xD;
             single brain metastasis treated with complete surgical resection or stereotactic&#xD;
             radiation therapy, radiological imaging has to demonstrate no recurrence or no brain&#xD;
             edema for at least 6 months from the end of the treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>December 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2013</results_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Avastin</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>AHSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: August 30. 2007 through November 2, 2010. All recruitment was done at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="45" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
        <time_frame>100 days after transplant</time_frame>
        <population>Study objectives were not meet, analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Fludarabine + Melphalan</title>
            <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Number or participants with no disease progression or death for any reason during first 100 days following transplantation. Participants followed every 3 months for first year.</description>
          <population>Study objectives were not meet, analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Fludarabine + Melphalan</title>
          <description>Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac toxicity, reduced ejection fraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mild depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hot flash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mild breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Face swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoto Ueno, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

